Friday, March 5, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

New Vaccine Development Platform Could Fight Deadly, Multi-Drug Resistant Bacteria

by Global Biodefense Staff
January 30, 2021
New Vaccine Development Platform Could Fight Deadly, Multi-Drug Resistant Bacteria

Interaction of resistant bacteria with human white cell. Credit: NIAID

A new vaccine development platform has proven effective in protecting against deadly, hard-to-treat infections caused by multi-drug resistant bacteria, thanks to a collaborative endeavor led by the Uniformed Services University (USU). This could ultimately help prevent battlefield infections, as well as common hospital-acquired infections in patients undergoing routine surgeries.

This research, “Radiation-Inactivated Acinetobacter baumannii Vaccine Candidates” was published this week in the journal Vaccines, as part of a special issue ‘Vaccines for Infectious and Chronic Diseases.’ The effort was led by Dr. Michael J. Daly, a professor in USU’s Department of Pathology, Dr. Gregory J. Tobin, president of Biological Mimetics, Inc., and Dr. Daniel Zurawski at the Walter Reed Army Institute of Research (WRAIR).

The rapid vaccine development platform, now shown to be highly effective against multi-drug resistant bacteria, has recently also been used to develop protective vaccines against RNA viruses: Venezuelan Equine Encephalitis Virus, Chikunguyna Virus, and Sabin polioviruses. Importantly, the USU platform developed by Daly’s team could be quickly adapted to generate inactivated whole-virus SARS-CoV-2 vaccines.

The multi-drug resistant A. baumannii bacteria first became a major threat to U.S. troops during the Gulf War. The bacteria cause a range of life-threatening illnesses including pneumonia, septicemia, and wound infections, but there are few treatment options when it comes to multi-drug resistant-bacteria. Since then, the World Health Organization (WHO) has listed A. baumannii in their highest category of pathogens posing an imminent threat to human health. Today in the U.S., there are about 45,000 hospital-acquired A. baumannii infections each year, and around one million globally.

“This will be a great benefit not only for our service members, as it could prevent trauma-related infections after battlefield injuries, but also to the general public, who are often exposed to this MDR pathogen in civilian hospital settings,” Daly said.

Funding for this study was provided through an STTR Phase II contract HDTRA 1-17-C-0030 from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense to BMI, Inc. with USU as the US Government partner, managed by the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF).

Radiation-Inactivated Acinetobacter baumannii Vaccine Candidates. Vaccines, 27 January 2021.

Article adapted from original story by Sarah Marshall, Uniformed Services University.

Tags: A. baumanniiAntimicrobialsChikungunyaDrug DevelopmentEditor PickHAIsPolioVenezuelan Equine Encephalitis

Related Posts

Medical Countermeasure Development
Funding News

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)
Funding News

UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

March 2, 2021
New Coronavirus Variant: Here Is What Scientists Know About B1525
Biosurveillance

New Coronavirus Variant: Here Is What Scientists Know About B1525

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?
Medical Countermeasures

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021
Load More

Latest News

Medical Countermeasure Development

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

March 2, 2021
New Coronavirus Variant: Here Is What Scientists Know About B1525

New Coronavirus Variant: Here Is What Scientists Know About B1525

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021

Upcoming Events

Mar 5
Virtual Event
March 2 - March 5

Effectiveness of Non-Vaccine Influenza Control Measures

Mar 6
Virtual Event
March 6 - March 10

CROI 2021 – Conference on Retroviruses and Opportunistic Infections

Mar 8
Virtual Event
March 8 - March 10

Quantum-Enabled Sensing and Imaging for Biology

Mar 8
Virtual Event
2:00 pm - 3:30 pm

TRB Webinar: Visualizing Effects of COVID-19 on Transportation: A One-Year Retrospective

Mar 9
Virtual Event
March 9 - March 11

The Current Global Governance Landscape for Influenza

View More
Tweets by GlobalBioD

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC